Tailoring treatment for PCOS phenotypes

References

• Teede H, Misso M, Costello M, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018. Natl Heal Med Res Counc. 2018;1:1–201.
   Google Scholar
• Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84(11):4006–4011.
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–2749. .
   Web of Science ®Google Scholar
• Fauser BCJM, Tarlatzis F, Chang J. et al et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41–47.
   Web of Science ®Google Scholar
• Papadakis G, Kandaraki EA, Tseniklidi E, et al. Polycystic ovary syndrome and NC-CAH: distinct characteristics and common findings. A systematic review. Front Endocrinol (Lausanne). 2019;10: DOI:10.3389/fendo.2019.00388.
   Web of Science ®Google Scholar
• Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10. DOI:10.1017/S1462399408000598
   PubMedGoogle Scholar
• Papadakis G, Kandaraki E, Papalou O, et al. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinologica. 2017;340–355. doi:10.23736/S0391-1977.17.02609-8
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): A prospective study of 634 women with PCOS. Clin Endocrinol (Oxf). 2007;67(5):735–742.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Christakou C, Palioura E, et al. Does polycystic ovary syndrome start in childhood? Pediatr Endocrinol Rev. 2008;5(4):904–911.
   Google Scholar
• Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des. 2012;18(3):270–282.
   Web of Science ®Google Scholar
• Merhi Z, Kandaraki EA, Diamanti-Kandarakis E. Implications and future perspectives of AGEs in PCOS pathophysiology. Trends Endocrinol Metab. 2019;30:150–162.
   PubMed Web of Science ®Google Scholar
• Kandaraki EA, Chatzigeorgiou A, Papageorgiou E, et al. Advanced glycation end products interfere in luteinizing hormone and follicle stimulating hormone signaling in human granulosa KGN cells. Exp Biol Med. 2018;243:29–33.
   Web of Science ®Google Scholar
• Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):1–29.
   Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164:53–60.
   Web of Science ®Google Scholar
• Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470–1474.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Álvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005;90(12):6364–6369. .
   Web of Science ®Google Scholar
• Li YJ, Han Y, He B. Effects of bariatric surgery on obese polycystic ovary syndrome: a systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15:942–950.
   Web of Science ®Google Scholar
• Machado Júnior AS, Ribeiro CBL, Santa-Cruz F, et al. The effect of sleeve gastrectomy on the hormonal profile of patients with polycystic ovary syndrome. Obes Surg. 2019;29:2415–2419.
   PubMed Web of Science ®Google Scholar
• Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2017;10:401–408.
   PubMed Web of Science ®Google Scholar
• van Bloemendaal L, Ten Kulve JS, La Fleur SE, et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221:T1-16.
   PubMed Web of Science ®Google Scholar
• Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17:1021–1032.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81(9):3299–3306.
   Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–1632.
   Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of d- chiro -inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340:1314–1320.
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab. 2005;90:60–65.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism. 2017;71:17–32.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Economou F, Palimeri S, et al. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci. 2010;1205:192–198.
   Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152:749–756.
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012. DOI:10.1002/14651858.CD003053.pub5.
   Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):1–235.
   Web of Science ®Google Scholar
• Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;59:30–38.
   PubMed Web of Science ®Google Scholar
• Unfer V, Facchinetti F, Orrù B, et al. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr Connect. 2017;6:647–658.
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2014;18:1896–1903.
   PubMed Web of Science ®Google Scholar
• Benelli E, Del Ghianda S, Di Cosmo C, et al. A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016;2016:1–5.
   PubMed Web of Science ®Google Scholar
• Furat Rencber S, Kurnaz Ozbek S, Eraldemlr C, et al. Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res. 2018;11. DOI:10.1186/s13048-018-0427-7.
   PubMed Web of Science ®Google Scholar
• Marti N, Bouchoucha N, Sauter KS, et al. Resveratrol inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities. PLoS One. 2017;12:e0174224.
   Web of Science ®Google Scholar
• Ortega I, Villanueva JA, Cress AB, et al. Resveratrol reduces steroidogenesis in rat ovarian theca-interstitial cells: the role of inhibition of AKT/PKB signaling pathway. Fertil Steril. 2012;98:S64.
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Wrotyńska-Barczyńska J, Spaczynski RZ, et al. Effects of resveratrol on polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2016;101:4322–4328.
   PubMed Web of Science ®Google Scholar
• King, McGill-Meeks, Beller, et al. Go Girls!—dance-based fitness to increase enjoyment of exercise in girls at risk for PCOS. Children. 2019;6:99.
   Google Scholar
• Grundy SM, Stone NJ, Chair V, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol circulation. Circulation. 2018;139(25):1082–1143.
   Google Scholar
• Palomba S, Falbo A, Chiossi G, et al. Lipid profile in nonobese pregnant women with polycystic ovary syndrome: A prospective controlled clinical study. Steroids. 2014;88:36–43.
   PubMed Web of Science ®Google Scholar
• Kogure GS, Lopes IP, Ribeiro VB, et al. The effects of aerobic physical exercises on body image among women with polycystic ovary syndrome. J Affect Disord. 2020;262:350–358.
   PubMed Web of Science ®Google Scholar
• Tasali E, Chapotot F, Leproult R, et al. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96:365–374.
   Web of Science ®Google Scholar
• Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2011;75:520–527.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Tendler DA, McMurray RG, et al. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract. 2005;11:319–324.
   PubMedGoogle Scholar
• Petit JM, Vergès B. GLP-1 receptor agonists in NAFLD. Diabetes Metab. 2017;43:2S28-2S33.
   PubMed Web of Science ®Google Scholar
• Papalou O, Diamanti-Kandarakis E. The role of stress in PCOS. Exp Rev Endocrinol Metab. 2017;12:87–95.
   PubMed Web of Science ®Google Scholar
• Vitek W, Alur S, Hoeger KM. Off-label drug use in the treatment of polycystic ovary syndrome. Fertil Steril. 2015;103:605–611.
   PubMed Web of Science ®Google Scholar
• Altshuler AL, Gaffield ME, Kiarie JN. The WHO’s medical eligibility criteria for contraceptive use: 20 years of global guidance. Curr Opin Obstet Gynecol. 2015;27:451–459.
   PubMed Web of Science ®Google Scholar
• K LM, R SJ, B SL, et al. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril. 1993;59(3):532–538.
   Web of Science ®Google Scholar
• Buhl Jørgensen SE, Starup J, Roos J, et al. Studies on the mode of action of clomiphene citrate. Acta Obstet Gynecol Scand. 1976;55:337–340.
   Web of Science ®Google Scholar
• Kerin JF, Liu JH, Phillipou G, et al. Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab. 1985;61:265–268.
   PubMed Web of Science ®Google Scholar
• Hager M, Hörath S, Frigo P, et al. Changes in serum markers of patients with PCOS during consecutive clomiphene stimulation cycles: a retrospective study. J Ovarian Res. 2019;12. doi:10.1186/s13048-019-0564-7.
   PubMed Web of Science ®Google Scholar
• Sachdeva G, Gainder S, Suri V, et al. Obese and non-obese polycystic ovarian syndrome: comparison of clinical, metabolic, hormonal parameters, and their differential response to clomiphene. Indian J Endocrinol Metab. 2019;23(2): 257–262.
   Google Scholar
• Kessel B, Hsueh AJW. Clomiphene citrate augments follicle-stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. Fertil Steril. 1987;47:334–340.
   Web of Science ®Google Scholar
• Miller PB, Soules MR. The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women. Obstet Gynecol. 1996;87:13–17.
   Web of Science ®Google Scholar
• Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331(12):771–776.
   Google Scholar
• Gorlitsky GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. Obstet Gynecol. 1978;51:265–269.
   PubMed Web of Science ®Google Scholar
• Gysler M, March CM, Mishell DR, et al. A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril. 1982;37:161–167.
   Web of Science ®Google Scholar
• Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119–129.
   Web of Science ®Google Scholar
• Kar S. Current evidence supporting “letrozole” for ovulation induction. J Hum Reprod Sci. 2013;6:93.
   Google Scholar
• Vause TDR, Cheung AP, Cheung AP, et al. Ovulation induction in polycystic ovary syndrome. J Obstet Gynaecol Canada. 2010;32:495–502.
   Google Scholar
• Zhang J, Tang L, Kong L, et al. Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women. Cochrane Database Syst Rev. 2019;7(7):1–52.
   Web of Science ®Google Scholar
• Thakre N, Homburg R. A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome. Exp Rev Endocrinol Metab. 2019;14:315–319.
   PubMed Web of Science ®Google Scholar
• Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105–1120.
   Web of Science ®Google Scholar
• Cosma M, Swiglo BA, Flynn DN, et al. Insulin sensitizers for the treatment of hirsutism: A systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93:1135–1142.
   Web of Science ®Google Scholar
• Spritzer PM, Lisboa KO, Mattiello S, et al. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587–594.
   PubMed Web of Science ®Google Scholar
• Raj SC, Raj MHG, Talbert LM, et al. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome. Obstet Gynecol Surv. 1983;38:110–111.
   Google Scholar
• JH CASEY. Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. Clin Endocrinol (Oxf). 1975;4:313–325.
   Web of Science ®Google Scholar
• Podfigurna A, Meczekalski B, Petraglia F, et al. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone). J Endocrinol Invest. 2020;43:483–492.
   Web of Science ®Google Scholar
• Teede H, Tassone EC, Piltonen T, et al. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019;91:479–489.
   PubMed Web of Science ®Google Scholar
• Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol (Oxf). 2000;52:379–382.
   PubMed Web of Science ®Google Scholar
• Irani M, Minkoff H, Seifer DB, et al. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab. 2014;99:E886-E890.
   PubMed Web of Science ®Google Scholar
• Dastorani M, Aghadavod E, Mirhosseini N, et al. The effects of vitamin D supplementation on metabolic profiles and gene expression of insulin and lipid metabolism in infertile polycystic ovary syndrome candidates for in vitro fertilization. Reprod Biol Endocrinol. 2018;16. DOI:10.1186/s12958-018-0413-3.
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, Policola C, Prioletta A, et al. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin Nutr. 2012;31:476–480.
   PubMed Web of Science ®Google Scholar
• Shojaeian Z, Sadeghi R, Roudsari RL. Calcium and Vitamin D supplementation effects on metabolic factors, menstrual cycles and follicular responses in women with polycystic ovary syndrome: a systematic review and meta-analysis. Casp J Intern Med. 2019;10(4):359–369.
   PubMed Web of Science ®Google Scholar
• Fazelian S, Rouhani MH, Bank SS, et al. Chromium supplementation and polycystic ovary syndrome: a systematic review and meta-analysis. J Trace Elem Med Biol. 2017;42:92–96.
   PubMed Web of Science ®Google Scholar
• Wang JG, Anderson RA, Graham GM, et al. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril. 2007;88:240–243.
   Web of Science ®Google Scholar
• Kort DH, Lobo RA. Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial. Obstet Gynecol Surv. 2015;70:94–95.
   Web of Science ®Google Scholar
• Mohammadi S, Bardei LK, Hojati V, et al. Anti-inflammatory effects of curcumin on insulin resistance index, levels of interleukin-6, C-reactive protein, and liver histology in polycystic ovary syndrome-induced rats. Cell J. 2017;19:425–433.
   Web of Science ®Google Scholar
• Jamilian M, Foroozanfard F, Bahmani F, et al. Effects of zinc supplementation on endocrine outcomes in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biol Trace Elem Res. 2016;170(2):271–278.
   Web of Science ®Google Scholar
• Khani B, Mardanian F, Fesharaki SJ. Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. J Res Med Sci. 2017;22. DOI:10.4103/jrms.JRMS_644_16
   PubMed Web of Science ®Google Scholar
• Guo Y, Qi Y, Yang X, et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2016;11(4):1–15.
   Web of Science ®Google Scholar
• Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:99–105.
   PubMed Web of Science ®Google Scholar
• Arentz S, Abbott JA, Smith CA, et al. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med. 2014;14. DOI:10.1186/1472-6882-14-511.
   Web of Science ®Google Scholar
• Dehghan A, Esfandiari A, Bigdeli SM. Alternative treatment of ovarian cysts with tribulus terrestris extract: a rat model. Reprod Domest Anim. 2012;47:e12-e15.
   PubMed Web of Science ®Google Scholar
• Hu Q, Jin J, Zhou H, et al. Crocetin attenuates DHT-induced polycystic ovary syndrome in mice via revising kisspeptin neurons. Biomed Pharmacother. 2018;107:1363–1369.
   Web of Science ®Google Scholar
• Jin J, Hu Q, Xu W, et al. Tanshinone IIA attenuates estradiol induced polycystic ovarian syndrome in mice by ameliorating FSHR expression in the ovary. Exp Ther Med. 2019. DOI:10.3892/etm.2019.7352.
   Web of Science ®Google Scholar
• Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones. 2014;13:65–73.
   PubMedGoogle Scholar
• Jinno M, Takeuchi M, Watanabe A, et al. Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod. 2011;26:604–610.
   PubMed Web of Science ®Google Scholar
• Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017;30:97–105.
   PubMed Web of Science ®Google Scholar
• Lim CED, Wong WSF. Current evidence of acupuncture on polycystic ovarian syndrome. Gynecol Endocrinol. 2010;26(6): 473–478.
   PubMed Web of Science ®Google Scholar
• Wiweko B, Indra I, Susanto C, et al. The correlation between serum AMH and HOMA-IR among PCOS phenotypes. BMC Res Notes. 2018;11. DOI:10.1186/s13104-018-3207-y.
   PubMedGoogle Scholar
• Morishita M, Endo T, Baba T, et al. Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. J Ovarian Res. 2018;11. DOI:10.1186/s13048-018-0395-y.
   PubMed Web of Science ®Google Scholar
• Lindheim L, Bashir M, Münzker J, et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study. PLoS One. 2017;12:e0168390.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Fu L, Li R, et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012;10. DOI:10.1186/1741-7015-10-153.
   Web of Science ®Google Scholar